Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK leads Access to Medicine Index 2014
The Access to Medicines Index published today has ranked GSK top for the fourth consecutive time.
-
New England Journal of Medicine publishes positive results from COMBI-v study of trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination
Results published in NEJM show that treatment with trametinib (Mekinist™) & Tafinlar™ improved OS compared to vemurafenib monotherapy
-
GSK launches first call for proposals for research in to non-communicable diseases in sub-Saharan Africa
GSK launched first call for proposals for its Africa NCD Open Lab, to support much-needed scientific research into NCDs in Africa.
-
GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) (1)
GSK announced submission to EMA for eltrombopag (Revolade™) for the treatment of patients with SAA who have insufficient response to IST.
-
GSK announces regulatory submissions for mepolizumab in severe eosinophilic asthma
GSK announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for patients with severe eosinophilic asthma
-
Results announcement for the third quarter 2014
GSK announces Q3 core EPS of 27.9p +5% CER excluding divestments and dividend of 19 pence per share
-
GSK update on current development status of the GSK/NIH Ebola vaccine candidate
GSK is working WHO to accelerate development of our investigational Ebola vaccine and to ramp up production as quickly as possible
-
Data published on Anoro® Ellipta® demonstrate improved lung function compared to tiotropium
Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro® Ellipta®.
-
Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris
Stiefel, announced phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris
-
GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director
GSK today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015.
-
GSK commits further funding to advance bioelectronics research with creation of 5 million Innovation Challenge Fund
GSK announced, $5 million ICF to encourage and advance collaborative research as part of its effort to develop bioelectronic medicines.
-
GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma
GSK updated results for Tafinlar® from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAFV600E metastatic melanoma.
-
GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors
GSK announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015
-
International collaboration to develop inhaled form of oxytocin to manage bleeding after childbirth in developing countries
GSK, Monash University, McCall MacBain Foundation, Grand Challenges Canada and Planet Wheeler Foundation join forces
-
GSK China Investigation Outcome
GlaxoSmithKline plc (GSK) announced that China ruled that GSK China Investment Co. Ltd has, according to Chinese law been found guilty
-
GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa
GSK announced a £5m collaboration with UK and SAMRC, to support much-needed research into NCDs in Africa, part of GSK Open Lab initiative.
-
GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions
GSK presented data at ERS Congress showing blood eosinophil levels may help predict patients with COPD when receiving an ICS regimen.
-
New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma
NEJM presented at ERS data from Phase III asthma studies of mepolizumab, an investigational IL-5 antagonist monoclonal antibody.
-
GSK announces first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study
GSK announced, phase IIIb/IV study to investigate combination therapy of ambrisentan and tadalafil in treatment naïve patients...
-
GSK, GOLD and the COPD Foundation announce formation of a new external expert Governance Board for the COPD Assessment Test (CAT)
At the ERS International Congress in Germany, GSK, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) ...